NCT07214753 A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
| NCT ID | NCT07214753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Severe Eosinophilic Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 335 participants |
| Start Date | 2025-12-20 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 335 participants in total. It began in 2025-12-20 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Eligibility Criteria
Inclusion Criteria: * Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma. * Benralizumab has been prescribed according to the approved label and local reimbursement criteria * Provision of signed Informed Consent Form (ICF) prior to any study-related activities * Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study). Exclusion Criteria: * Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment * Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial. * Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC). * Pregnant or lactating women. * patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement. * Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07214753 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Severe Eosinophilic Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07214753 currently recruiting?
Yes, NCT07214753 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07214753 trial being conducted?
This trial is being conducted at Salerno, Italy, Padova, Italy, Teramo, Italy, Treviso, Italy and 11 additional locations.
Who is sponsoring the NCT07214753 clinical trial?
NCT07214753 is sponsored by AstraZeneca. The trial plans to enroll 335 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.